Divalproex sodium in the treatment of pediatric psychiatric disorders

References Papers of special note have been highlighted as:• of interest•• of considerable interest

• Weissman MM, Bland RC, Canino GJ et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 276, 293–299 (1996).
   PubMed Web of Science ®Google Scholar
• Weissman MM, Bruce ML, Leaf PJ, Floric LP, Holzor C III. Affective disorders. In: Psychiatric Disorders in America: The Epidemiological Catchment Area Study. Robins LN, Reiger DA (Eds). The Free Press, NY, USA, 53–80 (1991).
   Google Scholar
• Lewinsohn PM, Klein DN, Seeley JR. Bipolar disorders in a community sample of older adolescents: Prevalence, phenomenology, comorbidity, and course. J. Am. Acad. Child Adolesc. Psychiatry34(4), 454–463(1995).
   PubMed Web of Science ®Google Scholar
• Steiner H, Dunne J, Ayres W et al. Practice parameters for the assessment and treatment of children and adolescents with conduct disorder. J. Am. Acad. Child Adolesc. Psychiatry 36(Suppl. 10), S122–S139 (1997).
   PubMed Web of Science ®Google Scholar
• McClellan J, Werry J, Ayres W. AACAP Official Action. Practice parameters for the assessment and treatment of children and adolescents with bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry 36(1), 138–157 (1997).
   PubMedGoogle Scholar
• Steiner H. Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. J. Clin. Psychiatry 64(10), 1183–1191(2003).
   PubMed Web of Science ®Google Scholar
• Donovan SJ, Stewart JW, Nunes EV et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am. J. Psychiatry 157(5), 818–820 (2000).
   PubMedGoogle Scholar
• Volkmar F, Cook EH Jr, Pomeroy J et al. Practice parameter for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. J. Am. Acad. Child Adolesc. Psychiatry 38(12), S32–S54 (1999).
   PubMed Web of Science ®Google Scholar
• Meunier G, Caraz G, Meunier Y, Eymard P, Aimard M. Properietes pharmacodynamiques de l’acide n-dipropylacetique. Therapie18, 435–438 (1963).
   PubMedGoogle Scholar
• Tunnicliff G. Actions of sodium valproate on the central nervous system. J. Physiol. Pharmacol.50(3), 347–365 (1999).
   PubMed Web of Science ®Google Scholar
• Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Progress Neurobiol. 58, 31–42 (1999).
   PubMed Web of Science ®Google Scholar
• Maes M, Calabrese JR. Mechanisms of action of valproate in affective disorders. In: Anticonvulsants in Mood Disorders. Marcel Dekker, Inc., NY, USA, 93–110 (1994).
   Google Scholar
• Whitton PS, Fowler LJ. The effect of valproic acid on 5-hydroxytryptamine and 5-hydroxyindoleacetic acid concentration in hippocampal dialysates in vivo. Eur. J. Pharmacol. 200, 167–169 (1991).
   PubMed Web of Science ®Google Scholar
• Biggs CS, Pearce BR, Fowler LJ, Whitton PS. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain – an in vivo microdialysis study. J. Neurochem. 59, 1702–1728 (1992).
   PubMed Web of Science ®Google Scholar
• Biggs CS, Pearce BR, Fowler LJ, Whitton PS. The effect of sodium valproate on extracellular GABA and other amino acids in the rat ventral hippocampus – an in vivo microdialysis study. Brain Res. 594, 138–142 (1992).
   PubMed Web of Science ®Google Scholar
• Baf MHM, Subhash MN, Lakshmana KM, Rao BSSR. Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem. Int. 24, 67–72 (1994).
   PubMed Web of Science ®Google Scholar
• Takebayashi M, Motohashi N, Saito H, Kagaya A, Yamawaki S. Effect of acute treatment with sodium valproate on catecholamine and serotonin synthesis in mouse cerebral cortex. Neuropsychobiology 32, 124–127 (1995).
   PubMedGoogle Scholar
• Kempf E, Mack G, Schleef C, Mandel P. Effect of valproic acid on brain serotonin metabolism in isolated and grouped rats. Pharmacol. Biochem. Behav. 17, 49–52 (1982).
   PubMed Web of Science ®Google Scholar
• Loscher W, Honack D. Valproate and its major metabolite e-2-en-valproate induce different effects on behavior and brain monoamine metabolism in rats. Eur. J. Pharmacol. 299, 61–67 (1996).
   PubMed Web of Science ®Google Scholar
• SuanL, McElroy MD, Harrison G, Pope MD Jr, Keck PE Jr. Valproate. In: Kaplan and Sadock’s Comprehensive Textbook of Psychiatry Volume Two.2289–2290 (2000).
   Google Scholar
• Kutcher S. Child and Adolescent Psychopharmacology. WB Saunders Company, PA, USA, 211–212 (1997).
   Google Scholar
• Donovan SJ. Divalproex treatment of disruptive adolescents: a report of 10 cases. J. Clin. Psychiatry58(1), 12–15 (1997).
   PubMedGoogle Scholar
• Chang KD, Dienes K, Blasey C, AdlemanN, Ketter T, Steiner H. Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms. J. Clin. Psychiatry64(8), 936–942 (2003).
   PubMedGoogle Scholar
• Findling RL, McNamara NK,Gracious BL et al. Combination lithium and divalproex sodium in pediatric bipolarity. J. Am. Acad. Child Adolesc. Psychiatry 42(8), 895–901(2003).
   PubMed Web of Science ®Google Scholar
• Henry CA, Zamvil LS, Lam C et al. Long term outcome with divalproex in children and adolescents with bipolar disorder. J. Child Adolesc. Psychopharmacol.13(4), 523–529 (2003).
   PubMed Web of Science ®Google Scholar
• Delbello MP, Schweirs ML, Rosenberg HL et al. A double blind randomized, placebo- controlled study of quetiapine as adjunctive treatment of adolescent mania. J. Am. Acad. Child Adolesc. Psychiatry 41(10), 1216–1233 (2002).
   PubMed Web of Science ®Google Scholar
• Wagner KD, Weller EB, Carlson GA et al. An open label trial of divalproex in children and adolescents with bipolar disorder. J. Am. Acad. Child. Adolesc. Psychiatry41(10), 1224–1231 (2002).
   PubMedGoogle Scholar
• Mota-Castillo M, Torruella A, Engels B et al. Valproate in very young children: an open case series with a brief follow up. J. Affect. Dis. 67, 193–197 (2001).
   PubMedGoogle Scholar
• Kowatch RA, Suppes T, Carmody TJ et al. Effect size of lithium, divalproex sodium and carbamazepine in children and adolescents with bipolar disorder. J. Am. Acad. Child. Adolesc. Psychiatry39(6), 713–720 (2000).
   PubMed Web of Science ®Google Scholar
• Papatheodorou G, Kutcher SP, Katic M et al. The efficacy and safety of divalproex sodium in the treatment of acute mania in adolescents and young adults: an open label trial. J. Clin. Psychopharmacol. 15(2), 110–116 (1995).
   PubMed Web of Science ®Google Scholar
• West SA, Keck PE, McElroy SL et al. Open trial of valproate in the treatment of adolescent mania. J. Child Adolescent Psychopharmacol. 4(4), 263–267 (1994).
   Web of Science ®Google Scholar
• Hollander E, Dolgoff-Kaspar R, Cartwright C et al. An open trial of divalproex sodium in autism spectrum disorder. J. Clin. Psychiatry 62(7), 530–534 (2001).
   PubMed Web of Science ®Google Scholar
• Isoherranen N, Yemen B, Bialer M. New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? Curr. Opin. Neurol. 16, 203–211(2003).
   PubMedGoogle Scholar
• Chang KD, Steiner H, Ketter TA. A psychiatric phenomenology of child and adolescent bipolar offspring. J. Am. Acad. Child Adolesc. Psychiatry39(4), 453–460 (2000).
   PubMed Web of Science ®Google Scholar
• Chang K. Pediatric psychopharmacology: an overview. In: Hand Book of Mental Health Interventions in Children and Adolescents.Steiner H (Ed.). Jossey-Bass, CA, USA, 247–255 (2004).
   Google Scholar
• Geller B, Cooper TB, Thomas B et al. Double- blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J. Am. Acad. Child. Adolesc. Psychiatry37(2), 171–178 (1998).
   PubMed Web of Science ®Google Scholar
  DeLong, RG, Aldershof A. Long-term experience with lithium treatment in childhood: correlation with clinical diagnosis. J. Am. Acad. Child Adolesc. Psychiatry 26(3), 389–394(1987).
   PubMed Web of Science ®Google Scholar
• Hassanyeh F, Davison K. Bipolar affective psychosis with onset before age 16 years. Br. J. Psychiatry 137, 530–539 (1980).
   PubMed Web of Science ®Google Scholar
• Strober M, Morrell W, Burroughs J. A family study of bipolar I disorder in adolescence: early onset of symptoms linked to increased familial loading and lithium resistance. J. Affect. Dis. Special Issue15(3) 255–268 (1988).
   PubMedGoogle Scholar
• Varanka TM, Weller RA, Weller EB, Fristad MA. Lithium treatment of manic episodes with psychotic features in prepubertal children. Am. J. Psychiatry 145(12) 1557–1559 (1988).
   PubMed Web of Science ®Google Scholar
• Connor DF, Glatt SJ, Lopez ID. Psychopharmacology and aggression. I: a meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J. Am. Acad. Child Adolesc. Psychiatry 41(3), 253–261 (2002).
   PubMed Web of Science ®Google Scholar
• DiMartino A, Tuchman RF. Antiepileptic drugs: affective use in autism spectrum disorders. Pediatr. Neurol. 25(3), 199–207 (2001).
   PubMed Web of Science ®Google Scholar
• Gagliano A, Germano E, Pustorino G et al. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J. Child Adolesc. Psychopharmacol.14(1), 39–47 (2004).
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Erfani S, Mohammadi MR. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. J. Clin. Pharm. Ther. 29(2), 145–150 (2004).
   PubMedGoogle Scholar
• Hollander E, Phillips AT, Yeh CC. Targeted treatments for symptom domains in child and adolescent autism. Lancet362(9385), 732–734 (2003).
   Google Scholar
• Davanzo PA, McCracken JT. Mood stabilizers in the treatment of juvenile bipolar disorder: advances and controversies. Child. Adoles. Psych. Clin. N. Am. 9(1) 159–182 (2000).
   PubMedGoogle Scholar
• Manji HK, Moore GJ, Chen G. Lithium up-regulates the cytoprotective protein bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J. Clin. Psych. 61(Suppl. 9), 82–96 (2000).
   Google Scholar
• Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biological Psych. 48(8), 740–754 (2000).
   Google Scholar
• Dutta S, Zhang Y, Selness DS et al. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res. 49(1), 1–10 (2002).
   PubMedGoogle Scholar
• Cloyd J C, Fischer JH, Kriel RL et al. Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin. Pharmacol. Ther. 53(1), 22–29 (1993).
   PubMed Web of Science ®Google Scholar
• Good CR, Feaster CS, Krecko VF. Tolerability of oral loading of divalproex sodium in child psychiatry inpatients. J. Child Adolesc. Psychopharmacol. 11(1), 53–57 (2001).
   PubMedGoogle Scholar
• Chang KD, Ketter TA. Special issues in the treatment of paediatric bipolar disorder. Expert Opin. Pharmacother. 2(4), 613–622 (2001).
   PubMedGoogle Scholar
• Lish J D, Gyulai LR, Susan M. A family history study of rapid-cycling bipolar disorder. Psych. Res. 48(1), 37–46 (1993).
   PubMedGoogle Scholar
• Perlis RH, Smoller JW, Fava M. The prevalence and clinical correlates of anger attacks during depressive episodes in bipolar disorder. J. Affec. Dis. 79(1–3), 291–295 (2004).
   PubMed Web of Science ®Google Scholar
• Chang K, Steiner H, Dienes K. Bipolar offspring: a window into bipolar disorder evolution. Bio. Psychiatry 53(11), 945–951 (2003).
   PubMedGoogle Scholar
• Steiner H, Saxena K, Chang K. Psychopharmacologic strategies for the treatment of aggression in juveniles. CNS Spectr. 8(4), 298–308 (2003).
   PubMed Web of Science ®Google Scholar
• Steiner H, Remsing L. AACAP workgroup on quality issues. Practice parameters for the assessment and treatment of children and adolescents with oppositional defiant disorder. J. Am. Acad. Child Adolesc. Psych. (2004) (In Press).
   Google Scholar
• Saxena K, Khanzode L, Robin-Durkin A, Delizonna L, Steiner H. Divaproex sodium in adolescent outpatient disruptive behavior disorders: an open label trial. American Psychchiatric Association Annual Conference, GA, USA (2005).
   Google Scholar
• Wang PW, Ketter TA. Pharmacokinetics of mood stabilizers and new anticonvulsants. Psychopharmacol. Bull. 36(1), 44–66 (2002).
   PubMedGoogle Scholar
• Samren EB, van Duijn CM, Koch S et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 38(9), 981–990 (1997).
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Stern AE, Bangs ME. Bipolar disorder in children and adolescents, Part II: valproate and other newer treatments. Int. Drug Therapy Newsletter 36(1), 1–8 (2001).
   Google Scholar
• Bryant AE III, Dreifuss FE. Valproic acid hepatic fatalities. III. US experience since 1986. Neurology46(2), 465–459 (1996).
   PubMed Web of Science ®Google Scholar
• Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N. Engl. J. Med. 329(19), 1383–1388 (1993).
   PubMed Web of Science ®Google Scholar
• Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J. Clin. Psychiatry 63(Suppl. 4), 42–55 (2002).
   PubMed Web of Science ®Google Scholar
• Bauer J, Jarre A, Klingmuller D, Elger CE. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res. 41(2), 163–167 (2000).
   PubMed Web of Science ®Google Scholar
  Rasgon NL, Altshuler LL, Gudeman D. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. J. Clin. Psychiatry 61(3), 173–178 (2000).
   PubMedGoogle Scholar
• Hao Y, Creson T, Zhang L et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J. Neurosci. 24(29), 6590–6509 (2004).
   PubMed Web of Science ®Google Scholar
• Davanzo P, Gunderson B, Belin T et al. Mood stabilizers in hospitalized children with bipolar disorder: a retrospective review. Psych. Clin. Neurosci. 57(5), 504–510 (2003).
   PubMed Web of Science ®Google Scholar
• Centorrino F, Kelleher JP, Berry JM et al. Pilot comparison of extended-release and standard preparations of divalproex sodium in patients with bipolar and schizoaffective disorders. Am. J. Psychiatry 160(7), 1348–1350 (2003).
   PubMedGoogle Scholar
• Horne RL, Cunanan C. Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium. J. Clin. Psychopharmacol. 23(2), 176–181(2003).
   Google Scholar
• Hirschfeld RM, Allen MH, McEvoy JP et al. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J. Clin. Psychiatry 60(12), 815–818 (1999).
   PubMedGoogle Scholar